Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.42 |
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 16/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 12/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8474830 | 0.78 | AGTR1 (0.48) | AGTR1AGTR2LTB4R2 | |
| SCHEMBL6949197 | 0.78 | HSD11B1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL6957300 | 0.78 | HSD11B1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL6953051 | 0.78 | HSD11B1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL684200 | 0.77 | LTB4R2 (0.50) | AGTR1LTB4R2 | |
| SCHEMBL8477688 | 0.77 | AGTR1 (0.50) | AGTR1AGTR2LTB4R2 | |
| SCHEMBL8524093 | 0.77 | AGTR1 (0.50) | AGTR1AGTR2LTB4R2 | |
| SCHEMBL3042 | 0.77 | AGTR1 (0.54) | AGTR1AGTR2LTB4R2 | |
| SCHEMBL8472989 | 0.77 | AGTR1 (0.47) | CMKLR1AGTR1AGTR2LTB4R2 | |
| SCHEMBL8260354 | 0.77 | LTB4R2 (0.52) | AGTR1LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICALS USA, INC. | 2004-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | AGTR1, AGTR2, TEK | CXCR4 2656/4885CMKLR1 147/4885AGTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.